Patient Safety Movement Foundation Announces Winners of 2020 Humanitarian Awards
The Patient Safety Movement Foundation (PSMF), a global non-profit committed to achieving zero preventable patient deaths by 2030, announced the winners of its 2020 Humanitarian Awards at a virtual ceremony on February 8, 2021. The recipients included Steve Burrows, Vonda Vaden Bates, Marty Hatlie and Barb Pelletreau. Each year the Humanitarian Awards recognize leaders who have made significant progress in the last year eliminating or raising awareness of preventable patient deaths.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210210005339/en/
Steve Burrows, Vonda Vaden Bates, Marty Hatlie and Barb Pelletreau were recognized by the Patient Safety Movement Foundation for their efforts eliminating and raising awareness of preventable patient deaths (Photo: Business Wire)
“To achieve our goal of zero preventable patient deaths by 2030, it is critical to unify people and collectively improve patient safety across the globe,” said David B. Mayer, MD, CEO of Patient Safety Movement Foundation. “We are pleased to honor each of these individuals for their remarkable efforts to spread public awareness of this important issue and improve the patient experience for everyone.”
The Humanitarian Award recipients were honored across three categories this year – the Judie Burrows award, Michael Seres award and Steven Moreau award. The Judie Burrows award was established to recognize an individual who has told a story of preventable harm or death that has made a significant impact in the public sphere in the last year. The Michael Seres award was designed in honor of lifelong patient safety advocate, Michael Seres, who passed away in May 2020. This award recognizes an individual who contributed to the advancement of person and family engagement, public awareness and public engagement in patient safety. The Steven Moreau award is given to a hospital administrator who possesses a zeal for improving patient safety at their hospital. This year’s recipients included:
- Steve Burrows, writer and director of the acclaimed documentary “Bleed Out,” was recognized with the Judie Burrows award for the impact his HBO film had in elevating the issues around patient safety in the public domain. His documentary follows the story of his mother, Judie Burrows, who experienced a preventable medical error during a partial hip surgery that afflicted her for the rest of her life. Since “Bleed Out” was released in December 2018 over 10 million viewers have watched the film on HBO. Prior to its release, Burrows, his wife Margo and their family thought they were alone, but within the first 24 hours of the film streaming they were inundated with thousands of Facebook messages from strangers who connected with Judie Burrows’ story.
- Vonda Vaden Bates has been passionate about advancing public awareness and engagement around the issue of preventable hospital deaths since losing her husband, Charles “Yogiraj” Bates II, to a preventable venous thromboembolism in 2012. She played an integral role in the conceptualization and success of the #uniteforsafecare campaign – a collaborative effort between the Patient Safety Movement Foundation, American Society of Anesthesiologists (ASA), The Leapfrog Group and International Society for Quality in Health Care (ISQua) to bring attention to system-wide improvements that will ensure better health worker and patient safety outcomes. Bates was recognized with the Michael Seres award for her efforts to advance public awareness and for helping make the #uniteforsafecare campaign and PSMF-hosted events in September 2020 a success.
- Marty Hatlie was also honored with the Michael Seres award. Hatlie has been a lifelong leader in patient safety since he served as executive director of the National Patient Safety Foundation. However, this humanitarian award acknowledges his exemplary work in the last 12 months. Hatlie served as one of the co-chairs for the March for Patient Safety turned #uniteforsafecare campaign. He dedicated much of 2019 and 2020 to launching the initiative.
- Barb Pelletreau, senior vice president of patient safety at CommonSpirit Health (formally known as Dignity Health), received the Steven Moreau award. Pelletreau was recognized for her leadership of the now 150+ hospital system, where she leads patient safety improvement efforts with transparency and candor. Under her leadership, Dignity Health became a PSMF 5-star hospital for making commitments in alignment with the Patient Safety Movement Foundation’s evidence-based Actionable Patient Safety Solutions (APSS) last year, reaffirming its dedication and commitment to zero preventable deaths.
The Patient Safety Movement Foundation launched the Humanitarian Awards in 2013 to recognize individuals whose work helps advance patient safety. To learn more about the awards and past winners, visit: https://patientsafetymovement.org.
To watch the award presentation, visit https://patient.sm/Humanitarian-Awards.
About the Patient Safety Movement Foundation: Each year, more than 200,000 people die unnecessarily in U.S. hospitals. Worldwide, 4.8 million lives are similarly lost. The Patient Safety Movement Foundation (PSMF) is a global non-profit on a mission to eliminate preventable deaths from hospital errors. PSMF uniquely brings patients and patient advocates, healthcare providers, medical technology companies, government, employers and private payers together under the same cause. From its Actionable Patient Safety Solutions and industry Open Data Pledge to its World Patient Safety, Science & Technology Summit and more, PSMF won’t stop fighting until it achieves zero. For more information, please visit patientsafetymovement.org to learn more, and follow PSMF on LinkedIn, Twitter, Instagram and Facebook.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210210005339/en/
Contact information
Leslie Licano, Beyond Fifteen Communications, Inc.
psmf@beyondfifteen.com | (949) 733-8679 ext.101
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte Announces Phase 1 Results for its TGFβR2×PD-1 Bispecific Antibody in Advanced Colorectal Cancer and KRAS G12D Inhibitor in Advanced Pancreatic Ductal Adenocarcinoma19.10.2025 20:30:00 EEST | Press release
Incyte (Nasdaq:INCY) announced the first clinical data evaluating its TGFβR2×PD-1 bispecific antibody (INCA33890) for patients with microsatellite stable (MSS) colorectal cancer; and its potent, selective and orally bioavailable KRAS G12D inhibitor (INCB161734) for patients with KRAS G12D mutations, specifically pancreatic ductal adenocarcinoma (PDAC). The data were featured in two oral sessions (Investigational immunotherapy; Abstract #1522MO and Developmental therapeutics; Abstract #916O, respectively) at the European Society of Medical Oncology (ESMO) Congress 2025. “The proof-of-concept data highlight the potential of INCA33890 and INCB161734 to address significant medical needs in patients with advanced solid tumors, including MSS colorectal cancer and PDAC,” said Pablo J. Cagnoni, M.D., President and Head of Research and Development, Incyte. “These results, including the favorable safety profiles as monotherapies, support continued clinical development. We look forward to explori
Corcept Presents ESMO 2025 Late-Breaker: Relacorilant Demonstrates Benefit in Patients with Platinum-Resistant Ovarian Cancer with Prior PARP Inhibitor Treatment19.10.2025 12:15:00 EEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today shared new late-breaking data from its pivotal Phase 3 ROSELLA trial of relacorilant plus nab-paclitaxel in patients with platinum-resistant ovarian cancer at the European Society for Medical Oncology (ESMO) 2025 Annual Meeting. The data demonstrated a progression-free survival (PFS) benefit for patients who experienced disease progression while on or after taking a PARP inhibitor (PARPi), a patient population with particularly poor prognosis. The presentation slides can be found here. The company also announced expansion of the Phase 2 BELLA trial in a poster session at ESMO, found here. New relacorilant data presented at ESMO demonstrated a consistent benefit in PARPi subgroups to overcome chemotherapy resistance. Relaco
Deciphera Presents 2-Year Efficacy and Safety Results from MOTION Phase 3 Study of ROMVIMZA ™ (vimseltinib) in Patients with Tenosynovial Giant Cell Tumor (TGCT) at the European Society for Medical Oncology Congress 202518.10.2025 14:00:00 EEST | Press release
Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the two-year efficacy and safety results from its MOTION Phase 3 study of vimseltinib in patients with TGCT in cases where surgical removal of the tumor is not an option will be presented as a poster during the 2025 European Society for Medical Oncology Congress (ESMO), taking place October 17-21 in Berlin, Germany. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251018921529/en/ “These long-term Phase 3 MOTION results add to the established body of evidence supporting vimseltinib as a best-in-class treatment for TGCT,” said Matthew L. Sherman, M.D., Chief Medical Officer of Deciphera. “TGCT often causes debilitating pain, stiffness and impaired mobility and these results demonstrate the durable benefit that vimseltinib can offer patients.” Summary of Data and Findings from the 2-year results of the MOTION Phase
ProAmpac Acquires International Paper’s Bag Converting Operations17.10.2025 17:09:00 EEST | Press release
ProAmpac, a global leader in flexible packaging and material science, has acquired the bag converting operations of International Paper (“IP”), a global leader in sustainable packaging. The acquisition expands ProAmpac’s converting capabilities, further advancing the company’s Fiberization of Packaging® strategy and enhancing its ability to deliver customized bag solutions for the grocery, convenience store, and quick-service restaurant markets. “Global demand for reliable, recyclable paper packaging continues to grow rapidly amid evolving consumer expectations and market trends redefining recyclability,” stated Greg Tucker, ProAmpac founder, vice chairman, and chief executive officer. “ProAmpac’s acquisition of IP’s bag operation supports our Fiberization of Packaging initiatives, helping us better serve customers by extending our expertise in material science to the US west coast with additional capabilities and redundancies,” continued Tucker. “IP’s bag business is strong, being bui
Pimicotinib Treatment Demonstrates Deep and Durable Tumor Responses and Continued Improvements in Pain and Function for Patients with TGCT17.10.2025 17:00:00 EEST | Press release
Merck, a leading science and technology company, today announced the presentation of longer-term results from the global Phase 3 MANEUVER trial evaluating pimicotinib, an investigational colony stimulating factor-1 receptor (CSF-1R) inhibitor in development by Abbisko Therapeutics Co., Ltd., for the treatment of patients with tenosynovial giant cell tumor (TGCT). This latest analysis showed that, with a median follow-up of 14.3 months, the objective response rate (ORR) for people treated with pimicotinib from the beginning of the study increased considerably to 76.2% (95% CI: 63.8, 86.0) by blinded independent review committee (BICR) per RECIST v1.1, from 54% at Week 25. The study also showed continued clinically meaningful improvements in key secondary endpoints related to patient outcomes such as pain and function. The safety profile was consistent with previously reported data. The results are being presented today in the Sarcoma mini-oral session at the European Society for Medical
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom